Research programme: cocaine abuse vaccine - Immunovaccine/Weill Cornell

Drug Profile

Research programme: cocaine abuse vaccine - Immunovaccine/Weill Cornell

Alternative Names: dAd5GNC; dAd5GNE

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weill Cornell Medical College
  • Developer Immunovaccine; Weill Cornell Medical College
  • Class Vaccines
  • Mechanism of Action Antigen-presenting-cell-modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cocaine abuse

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cocaine-abuse in USA (Parenteral)
  • 24 Oct 2012 Preliminary immunogenicity data from a preclinical studies in Cocaine abuse released by Immunovaccine
  • 12 Mar 2012 Preclinical trials in Cocaine abuse in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top